Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RCKT

Rocket Pharmaceuticals Inc

Dec 11 • 04:00PM ET

13.37

Dollar change -0.14
Percentage change -1.04	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT CRSP NTLA QURE BLUE EDIT ALLO SGMO ADVM VYGR

| Held by: VTI IWM VXF XBI VB IWO VBK IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.75	Insider Own	8.93%	Shs Outstand	91.12M	Perf Week	-1.55%
Market Cap	1.22B	Forward P/E	-	EPS next Y	-2.43	Insider Trans	-0.51%	Shs Float	83.02M	Perf Month	-20.70%
Income	-258.08M	PEG	-	EPS next Q	-0.73	Inst Own	98.49%	Short Float	12.51%	Perf Quarter	-29.41%
Sales	0.00M	P/S	-	EPS this Y	2.76%	Inst Trans	1.86%	Short Ratio	11.10	Perf Half Y	-41.18%
Book/sh	3.62	P/B	3.69	EPS next Y	14.35%	ROA	-52.01%	Short Interest	10.39M	Perf Year	-46.05%
Cash/sh	2.59	P/C	5.17	EPS next 5Y	41.70%	ROE	-59.27%	52W Range	12.62 - 32.53	Perf YTD	-55.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.09%	ROI	-73.20%	52W High	-58.89%	Beta	0.99
Dividend TTM	-	Quick Ratio	6.05	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.94%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	6.05	EPS Y/Y TTM	14.34%	Oper. Margin	-	RSI (14)	36.38	Volatility	6.78% 6.48%
Employees	268	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.13	Target Price	47.69
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	5.41%	Payout	-	Rel Volume	5.72	Prev Close	13.51
Sales Surprise	-	EPS Surprise	5.37%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	935.33K	Price	13.37
SMA20	-3.62%	SMA50	-15.58%	SMA200	-35.96%	Trades		Volume	5,353,115	Change	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35
Jul-08-22	Initiated	Raymond James	Outperform	$22
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy	$64
Feb-18-21	Initiated	Needham	Buy	$75
Dec-16-20	Initiated	UBS	Buy	$75
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy	$34
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy	$30
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy	$27
Feb-05-19	Initiated	Oppenheimer	Outperform	$39

Show Previous Ratings

Today 07:00AM	Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
Dec-10-24 04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-26-24 07:00AM	Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-18-24 11:00AM	Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference (Business Wire)
Nov-12-24 04:01PM	Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Associations 2024 Late-Breaking Science Sessions (Business Wire)
07:00AM	Loading…
Nov-08-24 07:00AM	Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-07-24 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Sep-17-24 07:00AM	Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease (Business Wire) +13.54%
Sep-10-24 07:00AM	Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors (Business Wire)
Aug-27-24 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-05-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jun-28-24 12:30PM	FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment (Investopedia)
07:27AM	Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) (Business Wire)
11:30AM	Loading…
Jun-05-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? (Zacks)
May-29-24 07:00AM	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (Business Wire)
May-10-24 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-07-24 11:26AM	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil (Zacks)
May-06-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-03-24 11:32AM	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia (Zacks)
Apr-02-24 06:00AM	Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia (Business Wire)
Mar-27-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? (Zacks)
Mar-26-24 04:01PM	Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team (Business Wire)
Feb-27-24 12:20PM	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-26-24 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (Business Wire)
07:00AM	Loading…
Feb-13-24 07:00AM	Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Jan-22-24 03:39AM	Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey) +5.61%
Jan-04-24 11:55AM	Amazon and Nvidia Stock Have a Lot More Growth Ahead, This Manager Says (Barrons.com)
Jan-02-24 04:01PM	Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 07:00AM	Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors (Business Wire)
Nov-23-23 12:16PM	Billionaire Lee Ainslies Top 10 Stock Picks (Insider Monkey)
Nov-15-23 11:17AM	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates (Zacks)
Nov-09-23 09:55AM	Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks) -7.15%
Nov-06-23 04:15PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.00%
04:04PM	Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Nov-05-23 07:30AM	With This Rally, Rocket Just Might Take Off (TheStreet.com)
Nov-02-23 06:26PM	Rocket Pharmaceuticals Stock Sees Improved Price Strength (Investor's Business Daily) +9.21%
Oct-27-23 02:49PM	Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher (Investor's Business Daily)
Oct-20-23 03:18AM	Should You Hold Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
Oct-19-23 07:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-02-23 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) -5.08%
Sep-26-23 04:01PM	Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference (Business Wire)
Sep-23-23 09:45AM	Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals (Motley Fool)
Sep-18-23 07:30AM	Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully (Motley Fool)
Sep-15-23 11:00AM	Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week (Zacks)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks) +13.28%
Sep-13-23 04:34PM	These Stocks Moved the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com) +38.85%
01:50PM	Stock Market Not Too Rattled By Inflation Data; Trucking Stock Gets A Bounce (Investor's Business Daily)
01:36PM	These Stocks Are Moving the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com)
12:30PM	Stock Market Weighs In On Inflation Data; Vaccine Maker Leads The S&P 500 (Investor's Business Daily)
12:23PM	What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today? (Benzinga)
12:15PM	Rocket Pharmaceuticals, Moderna rise; American Airlines, Spirit Airlines fall, Wednesday, 9/13/2023 (AP Finance)
11:56AM	Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday (Motley Fool)
10:54AM	Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential Value Driver. (Barrons.com)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
12:01AM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
Sep-12-23 04:02PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease (Business Wire)
Sep-06-23 04:05PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-10-23 07:14AM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +6.25%
Jun-12-23 04:34PM	3 Small-Cap Stocks You Cant Ignore Now (InvestorPlace)
Jun-09-23 09:24AM	Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag (Zacks)
Jun-08-23 07:00AM	Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-31-23 07:00AM	Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
May-23-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD) (Business Wire)
May-19-23 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-18-23 06:12AM	Heres Why Rocket Pharmaceuticals (RCKT) Stock Suffered in Q1 (Insider Monkey)
May-17-23 04:26PM	Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist (Yahoo Finance Video)
May-09-23 07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-04-23 04:21PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +5.24% +12.36%
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
May-03-23 04:01PM	Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference (Business Wire)
Apr-11-23 04:01PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Apr-04-23 04:01PM	Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage (Business Wire)
Mar-01-23 04:01PM	Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference (Business Wire) +5.41%
Feb-27-23 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (Business Wire)
Feb-09-23 04:01PM	Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
Feb-05-23 09:07AM	Even with Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock down 7.7% this week, insiders who bought recently netted around US$70k (Simply Wall St.)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-23-23 10:15AM	Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
09:55AM	Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet (Zacks)
Jan-09-23 04:01PM	Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease (Business Wire)
Jan-06-23 09:55AM	Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade (Zacks)
Jan-03-23 04:01PM	Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-22 06:00AM	Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting (Business Wire) -13.90%
Dec-12-22 10:00AM	Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire) +6.58%
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Dec-01-22 04:01PM	Rocket Pharmaceuticals Completes Acquisition of Renovacor (Business Wire) +8.10%
Nov-21-22 08:00AM	Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-16-22 07:59AM	A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (Simply Wall St.) -5.99%
Nov-03-22 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (Business Wire)

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Militello John	See Remarks	Nov 21 '24	Sale	13.05	1,224	15,978	49,310	Nov 25 04:05 PM
Patel Kinnari	See Remarks	Nov 21 '24	Sale	13.05	4,588	59,892	392,395	Nov 25 04:05 PM
Shah Gaurav	CEO	Nov 21 '24	Sale	13.05	11,091	144,782	707,328	Nov 25 04:05 PM
Wilson Martin	General Counsel	Nov 21 '24	Sale	13.05	1,175	15,338	63,560	Nov 25 04:05 PM
Patel Kinnari	Officer	Nov 21 '24	Proposed Sale	13.05	4,588	59,892		Nov 21 04:26 PM
Militello John	Officer	Nov 21 '24	Proposed Sale	13.05	1,224	15,978		Nov 21 04:06 PM
Wilson Martin	Officer	Nov 21 '24	Proposed Sale	13.05	1,175	15,338		Nov 21 03:58 PM
Shah Gaurav	Officer	Nov 21 '24	Proposed Sale	13.05	11,091	144,782		Nov 21 03:27 PM
White Mark Andrew	See Remarks	Oct 31 '24	Sale	16.62	3,080	51,205	69,140	Nov 04 04:06 PM
Militello John	See Remarks	Oct 31 '24	Sale	16.62	917	15,245	50,534	Nov 04 04:05 PM
Militello John	Officer	Oct 31 '24	Proposed Sale	16.62	917	15,245		Oct 31 03:34 PM
White Mark Andrew	Officer	Oct 31 '24	Proposed Sale	16.62	3,080	51,205		Oct 31 03:24 PM
Militello John	See Remarks	Aug 16 '24	Sale	18.50	1,064	19,688	51,451	Aug 20 04:26 PM
Patel Kinnari	See Remarks	Aug 16 '24	Sale	18.50	3,989	73,812	396,983	Aug 20 04:26 PM
Shah Gaurav	CEO	Aug 16 '24	Sale	18.50	9,650	178,564	718,419	Aug 20 04:26 PM
Wilson Martin	General Counsel	Aug 16 '24	Sale	18.50	1,027	19,004	64,735	Aug 20 04:26 PM
Militello John	Officer	Aug 16 '24	Proposed Sale	18.50	1,064	19,688		Aug 16 03:39 PM
Patel Kinnari	Officer	Aug 16 '24	Proposed Sale	18.50	3,989	73,810		Aug 16 03:29 PM
Wilson Martin	Officer	Aug 16 '24	Proposed Sale	18.50	1,027	19,003		Aug 16 03:23 PM
Shah Gaurav	Officer	Aug 16 '24	Proposed Sale	18.50	9,650	178,559		Aug 16 03:16 PM
Militello John	See Remarks	Jul 22 '24	Sale	23.02	812	18,688	52,515	Jul 24 04:05 PM
White Mark Andrew	See Remarks	Jul 08 '24	Sale	20.39	3,026	61,715	72,220	Jul 09 04:05 PM
Militello John	See Remarks	May 16 '24	Sale	23.35	1,079	25,195	53,327	May 20 04:36 PM
Shah Gaurav	CEO	May 14 '24	Option Exercise	0.00	17,662	0	646,134	May 20 04:33 PM
Shah Gaurav	CEO	May 16 '24	Sale	23.35	9,790	228,596	728,069	May 20 04:33 PM
Wilson Martin	General Counsel	May 14 '24	Option Exercise	0.00	2,420	0	21,100	May 20 04:29 PM
Wilson Martin	General Counsel	May 16 '24	Sale	23.35	1,048	24,471	65,762	May 20 04:29 PM
Patel Kinnari	See Remarks	May 14 '24	Option Exercise	0.00	9,543	0	301,824	May 20 04:26 PM
Patel Kinnari	See Remarks	May 16 '24	Sale	23.35	4,046	94,474	400,972	May 20 04:26 PM
Militello John	See Remarks	Apr 22 '24	Sale	22.87	833	19,051	54,406	Apr 24 04:06 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Option Exercise	4.34	70,000	303,940	165,160	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Option Exercise	4.34	29,624	128,627	124,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Sale	24.36	70,000	1,705,265	95,160	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Sale	24.05	10,000	240,520	114,784	Apr 16 05:45 PM
White Mark Andrew	See Remarks	Apr 08 '24	Sale	24.64	12,532	308,763	75,226	Apr 10 08:39 PM
Makker Gotham	Director	Mar 21 '24	Sale	28.43	274,000	7,790,943	365,912	Mar 25 08:58 PM
Militello John	See Remarks	Mar 21 '24	Sale	28.10	2,490	69,979	55,239	Mar 25 08:54 PM
Militello John	See Remarks	Feb 29 '24	Option Exercise	12.55	10,000	125,500	31,517	Mar 04 06:54 PM
Militello John	See Remarks	Feb 29 '24	Sale	29.84	10,000	298,450	21,517	Mar 04 06:54 PM
Wilson Martin	General Counsel	Feb 29 '24	Sale	29.33	4,100	120,257	18,680	Mar 04 06:48 PM
Wilson Martin	General Counsel	Feb 16 '24	Sale	29.84	3,576	106,701	6,136	Feb 21 08:54 PM
Patel Kinnari	See Remarks	Feb 16 '24	Sale	29.84	7,132	212,805	238,346	Feb 21 08:54 PM
Militello John	See Remarks	Feb 16 '24	Sale	29.84	3,238	96,615	13,195	Feb 21 08:54 PM
Shah Gaurav	CEO	Feb 16 '24	Sale	29.84	20,272	604,876	554,762	Feb 21 08:54 PM
Patel Kinnari	See Remarks	Feb 14 '24	Option Exercise	0.00	26,189	0	245,478	Feb 16 04:05 PM
Militello John	See Remarks	Feb 14 '24	Option Exercise	0.00	6,274	0	16,433	Feb 16 04:05 PM
Militello John	See Remarks	Jan 22 '24	Sale	27.20	638	17,356	10,159	Jan 23 04:22 PM
Militello John	See Remarks	Jan 18 '24	Option Exercise	0.00	1,586	0	10,797	Jan 22 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RCKT

Rocket Pharmaceuticals Inc

Upgrade your FINVIZ experience